Akari Therapeutics Investor Relations Material

Akari Therapeutics PLC is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune and inflammatory diseases. The company’s research primarily targets conditions involving the complement and leukotriene pathways, which play key roles in immune system regulation. Akari Therapeutics is headquartered in London, United Kingdom, and its shares are listed on the NASDAQ.